Coronary Revascularization Based on CMR Viability Study Vs Direct Revascularization in Ischemic Cardiomyopathy Patients

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Total Enrollment

15 participants

Study Classification

OBSERVATIONAL

Study Start Date

2022-02-01

Study Completion Date

2023-07-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The study aiming to demonstrate the baseline characteristics and outcomes of patients undergoing revascularization by PCI vs those kept only on medical treatment, based on CMR viability assessment.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

CMR for Prognosis Assessment in NSTEMI

NCT03516578

Myocardial Infarction

COMPLETED

Improved Prediction of Functional Recovery After Revascularisation Using Combined Assessment of Myocardial Ischaemia and Viability by CMR - Pilot Study

NCT03798652

Cardiovascular Diseases Ischemic Cardiomyopathy Cardiac Ischemia

UNKNOWN

A 10-Minute Cardiovascular Magnetic Resonance Protocol for Cardiac Disease

NCT04464655

Coronary Artery Disease Myocarditis Infiltrative Cardiomyopathy +7 more

RECRUITING

Predictive Value of Cardiovascular Magnetic Resonance Related Parameters in STEMI Patients After Primary PCI for Adverse Left Ventricular Remodeling and Major Adverse Cardiovascular Events

NCT04789564

Cardiovascular Diseases

COMPLETED

EARLY-MYO-CMR Registry

NCT03768453

ST-segment Elevation Myocardial Infarction (STEMI)

UNKNOWN

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Cardiac magnetic resonance (CMR) has an ever-increasing role in the assessment and management of patients with coronary artery disease (CAD). Advantages of CMR include the lack of ionizing radiation and its flexibility, high spatial resolution, and three-dimensional capabilities that enable imaging in any desired plane.

In the evaluation of patients with ischemic cardiomyopathy, CMR is primarily used in the setting of chronic CAD for the evaluation of myocardial ischemia and viability.

Left ventricular systolic dysfunction, resulting from coronary artery disease is reversible with revascularization in cases of hibernation and stunned myocardium. Revascularization is dependent not only on the presence but also the extent of viability, and a viable myocardium is necessary for functional recovery.

In a CMR study, in areas with dysfunctional myocardium as detected in cine sequences, the end diastolic wall thinning \>5.5 mm, the extent of subendocardial fibrosis together with response to low dose dobutamine were shown to predict functional recovery.

However, in the famous viability sub study of the STICH (Surgical Treatment for Ischemic Heart Failure) trial, there was a significant association between myocardial viability and outcome by univariate analysis, but not on multivariable analysis. Thereby, the value of CMR in this regards is still debatable.

So, according to the recent state of art paper from the American Heart Association, data is still limited regarding CMR use to guide revascularization strategies or predict outcomes in patients with severe LV dysfunction. The statement recommended that future trials should continue to address the clinical impact of specific modality-based strategies or multimodality strategies in guiding treatment in terms of patient outcomes.

On the other hand, appropriately guided coronary revascularization may go beyond providing recovery of myocardial systolic contractility by improving patient's functional class and heart failure symptoms, enhancing diastolic relaxation, reducing the burden of rhythm abnormalities, or decreasing the burden of polypharmacy, thereby reducing the risk of drug toxicity and improving quality of life. These additional benefits need also to be explored in clinical trials.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Ischemic Cardiomyopathy

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

RETROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

CMR viability study group

Diagnostic Test: CMR Basic CMR data including LV and RV volumes, SWMA reported, EF and wall thinning will be collected.

* SWMA from SSFP sequences will be reported and numbered according to the usual (1 normal, 2 hypokinetic, 3 akinetic, 4 dyskinetic, 5 aneurysmal).
* Data of viability assessed with LGE imaging with scar measurement using standard deviation method with SD of 4-5 will be used.
* AHA 17 segment model will be used as a reference for LV segmentation.
* Viability scoring will be calculated for each segment based on the transmurality index, in a semiautomated method, with no scar given 0, 1-25% subendocardial scar given score 1, 25-50% given 2, 50-75% given 3, \>75% as 4.
* Wall thinning will be given 0 or 1 score for each segment, with 1 given for \<6 mm thickness.

cardiac MRI

Intervention Type DEVICE

assessment of the viability using CMR

direct revascularization group

Direct Coronary revascularization

Percutaneous coronary intervention

Intervention Type PROCEDURE

direct revascularization using PCI

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

cardiac MRI

assessment of the viability using CMR

Intervention Type DEVICE

Percutaneous coronary intervention

direct revascularization using PCI

Intervention Type PROCEDURE

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

CMR PCI

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Patients \>18 years of age, with LVEF\<40%.
2. Patients presenting for viability assessment to Assiut university Heart Hospital, starting from October 2020 till September 2021, will be retrospectively recruited.
3. Patients with a coronary angiography that is amenable for revascularization. The decision and type of revascularization will be determined by the treating physicians.

Exclusion Criteria

1. Classic CMR and gadolinium-based dye contraindications including non-MRI compatible implants/foreign bodies (e.g. non-MRI compatible pacemaker, large pieces of shrapnel) and patients with eGFR\<30 ml/min/1.73 m2.
2. Patients with non-ischemic cardiomyopathy confirmed by both CMR and coronary angiography.

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No